Intrinsic value of HealthEquity - HQY

Previous Close

$84.55

  Intrinsic Value

$33.25

stock screener

  Rating & Target

str. sell

-61%

Previous close

$84.55

 
Intrinsic value

$33.25

 
Up/down potential

-61%

 
Rating

str. sell

We calculate the intrinsic value of HQY stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  26.10
  23.99
  22.09
  20.38
  18.84
  17.46
  16.21
  15.09
  14.08
  13.17
  12.36
  11.62
  10.96
  10.36
  9.83
  9.34
  8.91
  8.52
  8.17
  7.85
  7.57
  7.31
  7.08
  6.87
  6.68
  6.51
  6.36
  6.23
  6.10
  5.99
Revenue, $m
  289
  359
  438
  527
  627
  736
  856
  985
  1,123
  1,271
  1,429
  1,595
  1,769
  1,953
  2,145
  2,345
  2,554
  2,772
  2,998
  3,233
  3,478
  3,732
  3,996
  4,271
  4,556
  4,853
  5,162
  5,483
  5,818
  6,167
Variable operating expenses, $m
  210
  259
  314
  376
  445
  522
  605
  695
  791
  894
  995
  1,111
  1,232
  1,360
  1,494
  1,633
  1,779
  1,930
  2,088
  2,252
  2,422
  2,600
  2,784
  2,975
  3,174
  3,380
  3,595
  3,819
  4,052
  4,295
Fixed operating expenses, $m
  6
  6
  6
  7
  7
  7
  7
  7
  7
  7
  8
  8
  8
  8
  8
  8
  9
  9
  9
  9
  9
  10
  10
  10
  10
  11
  11
  11
  11
  12
Total operating expenses, $m
  216
  265
  320
  383
  452
  529
  612
  702
  798
  901
  1,003
  1,119
  1,240
  1,368
  1,502
  1,641
  1,788
  1,939
  2,097
  2,261
  2,431
  2,610
  2,794
  2,985
  3,184
  3,391
  3,606
  3,830
  4,063
  4,307
Operating income, $m
  73
  94
  118
  145
  175
  208
  244
  283
  325
  370
  426
  476
  529
  584
  643
  703
  766
  832
  901
  972
  1,046
  1,123
  1,203
  1,286
  1,372
  1,462
  1,556
  1,653
  1,754
  1,860
EBITDA, $m
  92
  116
  143
  173
  207
  244
  284
  328
  375
  425
  479
  535
  595
  657
  722
  790
  861
  935
  1,012
  1,092
  1,175
  1,261
  1,351
  1,444
  1,541
  1,642
  1,747
  1,856
  1,970
  2,088
Interest expense (income), $m
  0
  0
  0
  1
  1
  2
  2
  3
  3
  4
  5
  6
  6
  7
  8
  9
  10
  11
  12
  14
  15
  16
  17
  19
  20
  22
  23
  25
  26
  28
  30
Earnings before tax, $m
  73
  93
  117
  144
  173
  206
  241
  280
  321
  365
  420
  470
  522
  576
  633
  693
  755
  820
  887
  957
  1,030
  1,105
  1,184
  1,266
  1,351
  1,439
  1,531
  1,626
  1,726
  1,830
Tax expense, $m
  20
  25
  32
  39
  47
  56
  65
  75
  87
  98
  113
  127
  141
  156
  171
  187
  204
  221
  240
  258
  278
  298
  320
  342
  365
  389
  413
  439
  466
  494
Net income, $m
  53
  68
  85
  105
  126
  150
  176
  204
  234
  266
  307
  343
  381
  421
  462
  506
  551
  598
  648
  699
  752
  807
  864
  924
  986
  1,050
  1,118
  1,187
  1,260
  1,336

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  188
  233
  285
  342
  407
  478
  556
  639
  730
  826
  928
  1,035
  1,149
  1,268
  1,393
  1,523
  1,658
  1,800
  1,947
  2,100
  2,258
  2,423
  2,595
  2,773
  2,959
  3,151
  3,352
  3,561
  3,778
  4,004
Adjusted assets (=assets-cash), $m
  188
  233
  285
  342
  407
  478
  556
  639
  730
  826
  928
  1,035
  1,149
  1,268
  1,393
  1,523
  1,658
  1,800
  1,947
  2,100
  2,258
  2,423
  2,595
  2,773
  2,959
  3,151
  3,352
  3,561
  3,778
  4,004
Revenue / Adjusted assets
  1.537
  1.541
  1.537
  1.541
  1.541
  1.540
  1.540
  1.541
  1.538
  1.539
  1.540
  1.541
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
  1.540
Average production assets, $m
  58
  72
  88
  105
  125
  147
  171
  197
  225
  254
  286
  319
  354
  391
  429
  469
  511
  554
  600
  647
  696
  746
  799
  854
  911
  971
  1,032
  1,097
  1,164
  1,233
Working capital, $m
  6
  7
  9
  11
  13
  15
  17
  20
  22
  25
  29
  32
  35
  39
  43
  47
  51
  55
  60
  65
  70
  75
  80
  85
  91
  97
  103
  110
  116
  123
Total debt, $m
  6
  13
  21
  30
  39
  50
  62
  75
  89
  103
  119
  136
  153
  171
  190
  210
  231
  252
  275
  298
  323
  348
  374
  401
  430
  459
  490
  522
  555
  590
Total liabilities, $m
  29
  36
  44
  52
  62
  73
  85
  98
  112
  126
  142
  158
  176
  194
  213
  233
  254
  275
  298
  321
  346
  371
  397
  424
  453
  482
  513
  545
  578
  613
Total equity, $m
  159
  197
  241
  290
  345
  405
  471
  542
  618
  699
  786
  877
  973
  1,074
  1,180
  1,290
  1,405
  1,524
  1,649
  1,778
  1,913
  2,053
  2,198
  2,349
  2,506
  2,669
  2,839
  3,016
  3,200
  3,392
Total liabilities and equity, $m
  188
  233
  285
  342
  407
  478
  556
  640
  730
  825
  928
  1,035
  1,149
  1,268
  1,393
  1,523
  1,659
  1,799
  1,947
  2,099
  2,259
  2,424
  2,595
  2,773
  2,959
  3,151
  3,352
  3,561
  3,778
  4,005
Debt-to-equity ratio
  0.040
  0.060
  0.090
  0.100
  0.110
  0.120
  0.130
  0.140
  0.140
  0.150
  0.150
  0.150
  0.160
  0.160
  0.160
  0.160
  0.160
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
  0.170
Adjusted equity ratio
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847
  0.847

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  53
  68
  85
  105
  126
  150
  176
  204
  234
  266
  307
  343
  381
  421
  462
  506
  551
  598
  648
  699
  752
  807
  864
  924
  986
  1,050
  1,118
  1,187
  1,260
  1,336
Depreciation, amort., depletion, $m
  20
  22
  25
  28
  32
  36
  41
  45
  50
  56
  53
  59
  66
  72
  79
  87
  95
  103
  111
  120
  129
  138
  148
  158
  169
  180
  191
  203
  215
  228
Funds from operations, $m
  73
  90
  110
  133
  158
  186
  217
  249
  285
  322
  360
  402
  446
  493
  542
  593
  646
  701
  759
  818
  881
  945
  1,012
  1,082
  1,155
  1,230
  1,309
  1,390
  1,476
  1,564
Change in working capital, $m
  1
  1
  2
  2
  2
  2
  2
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
Cash from operations, $m
  72
  89
  109
  131
  156
  184
  214
  247
  282
  319
  357
  399
  443
  489
  538
  589
  642
  697
  754
  814
  876
  940
  1,007
  1,077
  1,149
  1,224
  1,303
  1,384
  1,469
  1,557
Maintenance CAPEX, $m
  -9
  -11
  -13
  -16
  -20
  -23
  -27
  -32
  -36
  -42
  -47
  -53
  -59
  -66
  -72
  -79
  -87
  -95
  -103
  -111
  -120
  -129
  -138
  -148
  -158
  -169
  -180
  -191
  -203
  -215
New CAPEX, $m
  -12
  -14
  -16
  -18
  -20
  -22
  -24
  -26
  -28
  -30
  -31
  -33
  -35
  -37
  -38
  -40
  -42
  -44
  -45
  -47
  -49
  -51
  -53
  -55
  -57
  -59
  -62
  -64
  -67
  -70
Cash from investing activities, $m
  -21
  -25
  -29
  -34
  -40
  -45
  -51
  -58
  -64
  -72
  -78
  -86
  -94
  -103
  -110
  -119
  -129
  -139
  -148
  -158
  -169
  -180
  -191
  -203
  -215
  -228
  -242
  -255
  -270
  -285
Free cash flow, $m
  51
  64
  80
  97
  117
  139
  163
  189
  218
  248
  278
  313
  349
  387
  427
  469
  513
  559
  606
  656
  707
  760
  816
  874
  934
  996
  1,061
  1,129
  1,199
  1,272
Issuance/(repayment) of debt, $m
  6
  7
  8
  9
  10
  11
  12
  13
  14
  15
  16
  16
  17
  18
  19
  20
  21
  22
  22
  23
  24
  25
  26
  27
  28
  29
  31
  32
  33
  35
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  6
  7
  8
  9
  10
  11
  12
  13
  14
  15
  16
  16
  17
  18
  19
  20
  21
  22
  22
  23
  24
  25
  26
  27
  28
  29
  31
  32
  33
  35
Total cash flow (excl. dividends), $m
  57
  71
  88
  106
  127
  150
  175
  202
  231
  263
  294
  329
  366
  405
  446
  489
  534
  580
  629
  679
  731
  786
  842
  901
  962
  1,026
  1,092
  1,160
  1,232
  1,307
Retained Cash Flow (-), $m
  -33
  -38
  -44
  -49
  -55
  -60
  -66
  -71
  -76
  -81
  -86
  -91
  -96
  -101
  -106
  -110
  -115
  -120
  -124
  -129
  -135
  -140
  -145
  -151
  -157
  -163
  -170
  -177
  -184
  -192
Prev. year cash balance distribution, $m
  220
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  244
  33
  44
  57
  72
  90
  109
  131
  155
  181
  207
  238
  270
  304
  341
  379
  419
  461
  504
  550
  597
  646
  697
  750
  805
  862
  922
  984
  1,048
  1,115
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  234
  30
  38
  47
  56
  65
  74
  82
  89
  95
  98
  101
  103
  102
  100
  96
  91
  85
  78
  70
  62
  54
  46
  38
  31
  25
  20
  15
  11
  8
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

HealthEquity, Inc. provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions. Its platform provides an ecosystem where consumers can access their tax-advantaged healthcare savings, compare treatment options and pricing, evaluate and pay healthcare bills, receive personalized benefit and clinical information, earn wellness incentives and make educated investment choices to help in their tax-advantaged healthcare savings. Its products and services include healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements and healthcare incentives. Its ecosystem primarily consists of HSA.

FINANCIAL RATIOS  of  HealthEquity (HQY)

Valuation Ratios
P/E Ratio 193.6
Price to Sales 28.3
Price to Book 19.2
Price to Tangible Book
Price to Cash Flow 109.4
Price to Free Cash Flow 152.5
Growth Rates
Sales Growth Rate 40.2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -74%
Cap. Spend. - 3 Yr. Gr. Rate 21.1%
Financial Strength
Quick Ratio NaN
Current Ratio 0.2
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 10.4%
Ret/ On Assets - 3 Yr. Avg. 9.6%
Return On Total Capital 11.2%
Ret/ On T. Cap. - 3 Yr. Avg. 10.7%
Return On Equity 11.2%
Return On Equity - 3 Yr. Avg. 10.7%
Asset Turnover 0.7
Profitability Ratios
Gross Margin 59.6%
Gross Margin - 3 Yr. Avg. 57.2%
EBITDA Margin 29.8%
EBITDA Margin - 3 Yr. Avg. 27.4%
Operating Margin 23%
Oper. Margin - 3 Yr. Avg. 20.9%
Pre-Tax Margin 22.5%
Pre-Tax Margin - 3 Yr. Avg. 20.4%
Net Profit Margin 14.6%
Net Profit Margin - 3 Yr. Avg. 13.1%
Effective Tax Rate 35%
Eff/ Tax Rate - 3 Yr. Avg. 35.7%
Payout Ratio 0%

HQY stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the HQY stock intrinsic value calculation we used $229.525 million for the last fiscal year's total revenue generated by HealthEquity. The default revenue input number comes from 0001 income statement of HealthEquity. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our HQY stock valuation model: a) initial revenue growth rate of 26.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for HQY is calculated based on our internal credit rating of HealthEquity, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of HealthEquity.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of HQY stock the variable cost ratio is equal to 73.5%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $6 million in the base year in the intrinsic value calculation for HQY stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for HealthEquity.

Corporate tax rate of 27% is the nominal tax rate for HealthEquity. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the HQY stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for HQY are equal to 20%.

Life of production assets of 5.4 years is the average useful life of capital assets used in HealthEquity operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for HQY is equal to 2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $346.274 million for HealthEquity - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 62.046 million for HealthEquity is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of HealthEquity at the current share price and the inputted number of shares is $5.2 billion.

RELATED COMPANIES Price Int.Val. Rating
UNH UnitedHealth G 264.94 561.84  str.buy
AET Aetna 209.36 153.46  sell
MGLN Magellan Healt 56.24 321.06  str.buy
CRVL Corvel 64.75 35.50  sell

COMPANY NEWS

▶ Dow Today Plunges 400 Points; Why Leading Stocks Are In A Bear Market   [Nov-19-18 03:09PM  Investor's Business Daily]
▶ Stock Market Posts Volatile Gains; Is Apple Stock Nearing A Bottom?   [Nov-13-18 10:14AM  Investor's Business Daily]
▶ Dow, Nasdaq Rally Strong As Growth Stocks Show These 5 Bullish Signs   [Nov-07-18 03:30PM  Investor's Business Daily]
▶ Top Stocks Today: Applied Materials, Lam Research Lead Semiconductor Rally   [Nov-01-18 03:02PM  Investor's Business Daily]
▶ Here's My Top Stock to Buy in October   [Oct-08-18 09:46PM  Motley Fool]
▶ HealthEquity to Present at Investor Conference   [Sep-18-18 04:02PM  GlobeNewswire]
▶ The Motley Fool Sits Down With the CEO of HealthEquity   [Sep-14-18 11:07AM  Motley Fool]
▶ Stock Market Today: Nasdaq Hit In Early Trade; Pot Stocks Rip Higher   [Sep-05-18 09:55AM  Investor's Business Daily]
▶ HealthEquity Beats Earnings Views, Raises Outlook; But Stock Falls   [Sep-04-18 05:09PM  Investor's Business Daily]
▶ HealthEquity: Fiscal 2Q Earnings Snapshot   [04:15PM  Associated Press]
▶ This Medtech Company Is Posting Explosive Growth   [Aug-27-18 11:25AM  Motley Fool]
▶ 3 Small-Cap Healthcare Stocks for Your Watch List   [Aug-26-18 07:15PM  Motley Fool]
▶ HealthEquity Introduces New COO   [Jun-21-18 04:15PM  GlobeNewswire]
▶ 3 Top Healthcare Stocks to Buy in June   [Jun-15-18 10:21AM  Motley Fool]
▶ This Top IBD 50 Stock Beats Earnings Estimates, Lifts Guidance   [04:23PM  Investor's Business Daily]
▶ HealthEquity: Fiscal 1Q Earnings Snapshot   [04:18PM  Associated Press]
▶ HealthEquity Inc to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Dow Gains Nearly 200 Points; This FANG Stock Falls On Report   [10:19AM  Investor's Business Daily]
▶ How to Find a Growth Stock   [May-30-18 02:54PM  Motley Fool]
▶ Best HSA Providers By Fees, Features And Investment Options   [Apr-20-18 08:40AM  Investor's Business Daily]
▶ Is There Now An Opportunity In HealthEquity Inc (NASDAQ:HQY)?   [Apr-18-18 06:29AM  Simply Wall St.]
▶ Is HealthEquity (HQY) a Great Growth Stock?   [Apr-10-18 08:55AM  Zacks]
▶ HealthEquity Appoints Angelique Hill as EVP of Operations   [Apr-06-18 04:10PM  GlobeNewswire]
▶ The 1 Stock I'd Buy in April   [Mar-29-18 07:25PM  Motley Fool]
▶ HealthEquity Appoints New Director to the Board   [Mar-28-18 04:07PM  GlobeNewswire]
▶ Forget Bitcoin: You're Better Off Buying These 3 Stocks   [Mar-27-18 06:11PM  Motley Fool]
▶ Company News For Mar 21, 2018   [10:29AM  Zacks]
▶ Why MuleSoft, Square, and HealthEquity Jumped Today   [Mar-20-18 04:31PM  Motley Fool]
▶ Here's Why HealthEquity Is Up 12% Today   [03:43PM  Motley Fool]
▶ HealthEquity meets 4Q profit forecasts   [Mar-19-18 04:26PM  Associated Press]
▶ IBD 50 Stock HealthEquity Beats Q4 Forecasts As HSAs Grow   [04:21PM  Investor's Business Daily]
▶ HealthEquity Inc to Host Earnings Call   [12:30PM  ACCESSWIRE]
▶ HealthEquity Q4 Earnings Preview   [07:33AM  Benzinga]
▶ HealthEquity Sets Date to Announce Year-end Results   [Mar-05-18 05:13PM  GlobeNewswire]
▶ HealthEquity Stock Plunges On HSA Enrollment Fears   [Feb-23-18 10:27AM  Investor's Business Daily]
▶ Stocks Inch Up At Open: Amazon Target Raised, Fed Minutes Loom   [Feb-21-18 09:38AM  Investor's Business Daily]
▶ HealthEquity to Present at Investor Conferences   [Feb-20-18 04:04PM  GlobeNewswire]
▶ Stocks Mixed As Walmart Dents Dow, But Chips Hoist Nasdaq   [01:35PM  Investor's Business Daily]
▶ As Apple, Netflix And Cisco Rise, This IBD 50 Stock Breaks Out   [09:34AM  Investor's Business Daily]
▶ Indexes Extend Win Streaks; One FANG Name Shines, Another Lags   [Feb-13-18 04:20PM  Investor's Business Daily]
▶ Does HealthEquity Incs (NASDAQ:HQY) PE Ratio Warrant A Sell?   [Feb-06-18 07:59PM  Simply Wall St.]
▶ HealthEquity Reports Year-End Sales Metrics   [04:05PM  GlobeNewswire]
▶ HealthEquity Inc to Host Earnings Call   [01:00PM  ACCESSWIRE]
▶ HealthEquity to Announce Year-End HSAs and Custodial Assets   [Jan-23-18 06:06PM  GlobeNewswire]
▶ At $49.41, Is HealthEquity Inc (NASDAQ:HQY) A Buy?   [Jan-10-18 05:22AM  Simply Wall St.]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.